Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
|Articles|November 2, 2016
- Pharmaceutical Technology-11-02-2016
- Volume 40
- Issue 11
Biomolecule Separator Reduces Sample Absorption
Yarra 1.8µm SEC-X300 from Phenomenex is a high-resolution gel filtration chromatography (GFC)/aqueous size-exclusion chromatography (SEC) column for the separation of high molecular weight biomolecules on high-performance liquid chromatography and ultra-high pressure liquid chromatography systems.
Yarra 1.8µm SEC-X300 from Phenomenex is a high-resolution gel filtration chromatography (GFC)/aqueous size-exclusion chromatography (SEC) column for the separation of high molecular weight biomolecules on high-performance liquid chromatography and ultra-high pressure liquid chromatography systems. With a separation range of 10K to 700KDa and high efficiency, SEC-X300 is ideal for separating and characterizing monoclonal antibody aggregates, antibody drug conjugates, and biosimilars in drug discovery and development research. Yarra SEC-X150 and -X300 columns typically operate at backpressures below 3500 psi. The proprietary Yarra surface chemistry, combined with bio-inert column hardware, reduce sample adsorption.
Articles in this issue
almost 10 years ago
The Human Factor in Inspectionsalmost 10 years ago
Application of QbD and QRM to Analytical Method Validationalmost 10 years ago
Biosimilars to Drive Modern Manufacturing Approachesalmost 10 years ago
Cleaning Validation in Continuous Manufacturingalmost 10 years ago
Lubrication in Continuous Tubular Powder Blendersalmost 10 years ago
Integrated Membrane for Single-Use Filtration Assembliesalmost 10 years ago
Dual-Shaft Mixers Provide Efficient Turnoveralmost 10 years ago
Workstations Allow for Continuous Control of Cell Culture Processesalmost 10 years ago
Dissolution TestingRelated to this article
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
3
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
4
Why BMS, Roche, and LGM Pharma Outsourced Key Capabilities
5